Research programme: Wnt signalling pathway inhibitors - The Genetics Company

Drug Profile

Research programme: Wnt signalling pathway inhibitors - The Genetics Company

Alternative Names: TGC-0011570; TGC-0011576; TGC-0011589; TGC-0012296

Latest Information Update: 07 Jan 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator The Genetics Company
  • Class Small molecules
  • Mechanism of Action BCL9 protein inhibitors; PYGO2 protein inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Jan 2011 Discontinued - Preclinical for Cancer in Switzerland (unspecified route)
  • 15 Dec 2008 Preclinical development is ongoing in Switzerland
  • 07 Dec 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top